These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 37674935)

  • 1. COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.
    Bostanghadiri N; Ziaeefar P; Mofrad MG; Yousefzadeh P; Hashemi A; Darban-Sarokhalil D
    Biomed Res Int; 2023; 2023():1879554. PubMed ID: 37674935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.
    Patel R; Kaki M; Potluri VS; Kahar P; Khanna D
    Hum Vaccin Immunother; 2022 Dec; 18(1):2002083. PubMed ID: 35130825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses.
    Muhar BK; Nehira J; Malhotra A; Kotchoni SO
    J Pharm Pract; 2023 Aug; 36(4):953-966. PubMed ID: 35723017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COVID-19 pandemic: viral variants and vaccine efficacy.
    Ciotti M; Ciccozzi M; Pieri M; Bernardini S
    Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.
    Abd El-Aziz TM; Stockand JD
    Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Different Perspective on the COVID-19 Pandemic: Origin of the Outbreak (Part 1).
    Barbari A
    Exp Clin Transplant; 2024 Jan; 22(Suppl 2):1-14. PubMed ID: 38385593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.
    Abdolmaleki G; Taheri MA; Paridehpour S; Mohammadi NM; Tabatabaei YA; Mousavi T; Amin M
    Daru; 2022 Dec; 30(2):379-406. PubMed ID: 36050585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19: From emerging variants to vaccination.
    Senevirathne TH; Wekking D; Swain JWR; Solinas C; De Silva P
    Cytokine Growth Factor Rev; 2024 Apr; 76():127-141. PubMed ID: 38135574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
    Raman R; Patel KJ; Ranjan K
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern.
    Al-Fattah Yahaya AA; Khalid K; Lim HX; Poh CL
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
    MacPherson A; Hutchinson N; Schneider O; Oliviero E; Feldhake E; Ouimet C; Sheng J; Awan F; Wang C; Papenburg J; Basta NE; Kimmelman J
    Ann Intern Med; 2021 Mar; 174(3):326-334. PubMed ID: 33226855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary.
    Pather S; Muik A; Rizzi R; Mensa F
    Expert Rev Vaccines; 2024 Dec; 23(1):463-466. PubMed ID: 38578120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.